Table 1.
Immunohistochemical details of the metastatic lesions
| Immunohistochemical markers | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time point | Tissue investigated | Procedure | CgA | SYP | CD56 | INSM1 | ISLET1 | Cyto-keratins | Vimentin | Melan A | HMB45 | SOX10 | Diagnosis |
| April 2019 | Chest wall | Core-needle biopsy | – | + (100%) | + (100%) | + (100%) | + (10%) | – * | + (100%) | – | – | n.d. | NEC |
| June 2019 | Femur | Surgical excision | – | + (15%) | + (100%) | n.d. | n.d. | – | + (100%) | + (30%) | + (30%) | + (100%) | MM-NE |
CgA chromogranin A, HMB45 human melanoma black 45, INSM1 insulinoma-associated protein 1, ISLET1 ISL LIM homeobox 1, Melan A melanoma antigen, MM-NE malignant melanoma with neuroendocrine differentiation, n.d. not determined, – negative staining, NEC neuroendocrine carcinoma, SYP synaptophysin
*Focal cytokeratin OSCAR immunoreactivity noted in few tumor cells – uncertain significance